S*BIO starts dosing in Phase 2 advanced lymphoid malignancies drug trial
The Phase 2 trial is designed to investigate the efficacy and safety of SB1518 in patients with advanced lymphoid malignancies. In the trial, three patients demonstrated partial response
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.